Abstract
Apoptosis ligand 2 tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to a small subset of proapoptotic protein ligands in the TNF superfamily. This subset, which also includes Fas ligand and TNF-α, can activate the extrinsic apoptotic cell death pathway on binding to cognate death receptors at the cell surface. Over the past 10 years, Apo2L/TRAIL has emerged as a promising candidate for cancer therapy, on the basis of its unique ability to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells. Herein, we review key advances in understanding the molecular events that control apoptosis signaling by Apo2L/TRAIL, which may aid in the development of cancer therapies based on the extrinsic apoptotic pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME et al. (2009). Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 136: 2365–2376 e1-7.
Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL et al. (2003). Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 100: 11445–11450.
Almasan A, Ashkenazi A . (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337–348.
Ashkenazi A . (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420–430.
Ashkenazi A, Dixit VM . (1998). Death receptors: signaling and modulation. Science 281: 1305–1308.
Ashkenazi A, Holland P, Eckhardt SG . (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621–3630.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155–162.
Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM et al. (2006). Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA 103: 10283–10288.
Barnhart BC, Alappat EC, Peter ME . (2003). The CD95 type I/type II model. Semin Immunol 15: 185–193.
Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D et al. (2009). Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J Exp Med 206: 1727–1737.
Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM et al. (2003). A unified model for apical caspase activation. Mol Cell 11: 529–541.
Bodmer JL, Meier P, Tschopp J, Schneider P . (2000). Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 275: 20632–20637.
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005–1009.
Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP et al. (2009). Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell 35: 830–840.
Casella CR, Finkel TH . (1997). Mechanisms of lymphocyte killing by HIV. Curr Opin Hematol 4: 24–31.
Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC et al. (1999). 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11: 253–261.
Chaigne-Delalande B, Mahfouf W, Daburon S, Moreau JF, Legembre P . (2009). CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death Differ 16: 1654–1664.
Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F et al. (2007). Palmitoylation is required for efficient Fas cell death signaling. EMBO J 26: 209–220.
Chan FK . (2007). Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37: 101–107.
Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ . (2000). A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351–2354.
Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. (2002). c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21: 3704–3714.
Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L . (1997). Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7: 821–830.
Chen M, Orozco A, Spencer DM, Wang J . (2002). Activation of initiator caspases through a stable dimeric intermediate. J Biol Chem 277: 50761–50767.
Chen X, Kandasamy K, Srivastava RK . (2003). Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63: 1059–1066.
Chowdhury I, Tharakan B, Bhat GK . (2006). Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol Biol Lett 11: 506–525.
Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. (2005). Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102: 18099–18104.
Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS et al. (2005). TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 83: 511–519.
Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ . (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356–1361.
Danial NN, Korsmeyer SJ . (2004). Cell death: critical control points. Cell 116: 205–219.
Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF et al. (1997). Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186: 1165–1170.
Deng Y, Lin Y, Wu X . (2002). TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16: 33–45.
Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM et al. (1998). IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215–2223.
Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, Morici LA et al. (2004). TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877–889.
Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E . (2007). Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12: 1533–1541.
Eckelman BP, Salvesen GS, Scott FL . (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988–994.
Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I . (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22: 3842–3852.
Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J et al. (2006). Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ 13: 1619–1630.
Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T et al. (2001). Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 18: 311–316.
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363–14367.
Esposti MD, Erler JT, Hickman JA, Dive C . (2001). Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Mol Cell Biol 21: 7268–7276.
Fadeel B, Orrenius S, Zhivotovsky B . (1999). Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 266: 699–717.
Feig C, Tchikov V, Schutze S, Peter ME . (2007). Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J 26: 221–231.
Finnberg N, Klein-Szanto AJ, El-Deiry WS . (2008). TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118: 111–123.
Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM et al. (2001). Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7: 1688–1697.
Fulda S, Meyer E, Debatin KM . (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283–2294.
Gonzalvez F, Bessoule JJ, Rocchiccioli F, Manon S, Petit PX . (2005a). Role of cardiolipin on tBid and tBid/Bax synergistic effects on yeast mitochondria. Cell Death Differ 12: 659–667.
Gonzalvez F, Pariselli F, Dupaigne P, Budihardjo I, Lutter M, Antonsson B et al. (2005b). tBid interaction with cardiolipin primarily orchestrates mitochondrial dysfunctions and subsequently activates Bax and Bak. Cell Death Differ 12: 614–626.
Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ et al. (2008). Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol 183: 681–696.
Grassme H, Cremesti A, Kolesnick R, Gulbins E . (2003). Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22: 5457–5470.
Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K et al. (2001). CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 276: 20589–20596.
Green DR, Amarante-Mendes GP . (1998). The point of no return: mitochondria, caspases, and the commitment to cell death. Results Probl Cell Differ 24: 45–61.
Green DR, Reed JC . (1998). Mitochondria and apoptosis. Science 281: 1309–1312.
Grinberg M, Sarig R, Zaltsman Y, Frumkin D, Grammatikakis N, Reuveny E et al. (2002). tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis. J Biol Chem 277: 12237–12245.
Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI et al. (2008). TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118: 100–110.
Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.
Hayakawa K, Takemura G, Koda M, Kawase Y, Maruyama R, Li Y et al. (2002). Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 105: 3039–3045.
Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y . (2001). Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 166: 1314–1319.
Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E et al. (2000). Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19: 5477–5486.
Hughes MA, Harper N, Butterworth M, Cain K, Cohen GM, MacFarlane M . (2009). Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol Cell 35: 265–279.
Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. (1999). Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4: 563–571.
Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. (2000). A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633–640.
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. (1997). Inhibition of death receptor signals by cellular FLIP. Nature 388: 190–195.
Ishimura N, Isomoto H, Bronk SF, Gores GJ . (2006). Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290: G129–G136.
Jin Z, El-Deiry WS . (2006). Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 26: 8136–8148.
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR et al. (2009). Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721–735.
Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC et al. (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035–1039.
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611–620.
Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P et al. (2001). Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639–46646.
Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM . (2007). Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 282: 12831–12841.
Krammer PH . (2000). CD95's deadly mission in the immune system. Nature 407: 789–795.
Kroemer G, Dalaporta B, Resche-Rigon M . (1998). The mitochondria death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619–642.
Krueger A, Baumann S, Krammer PH, Kirchhoff S . (2001). FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247–8254.
Labrinidis A, Liapis V, Thai le M, Atkins GJ, Vincent C, Hay S et al. (2008). Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 111: 5411–5412; autor reply 5413.
Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T et al. (1996). Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2: 80–86.
Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L et al. (2008). DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 68: 909–917.
Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH . (2003). Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice. Nat Immunol 4: 255–260.
Lavrik I, Golks A, Krammer PH . (2005a). Death receptor signaling. J Cell Sci 118: 265–267.
Lavrik IN, Golks A, Krammer PH . (2005b). Caspases: pharmacological manipulation of cell death. J Clin Invest 115: 2665–2672.
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383–385.
Le Roy C, Wrana JL . (2005). Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6: 112–126.
LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. (2002). Tumor-cell resistance to death receptor—induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274–281.
LeBlanc HN, Ashkenazi A . (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66–75.
Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S et al. (2006). The role of receptor internalization in CD95 signaling. EMBO J 25: 1009–1023.
Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY et al. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59: 5683–5686.
Li H, Zhu H, Xu CJ, Yuan J . (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501.
Li J, Yuan J . (2008). Caspases in apoptosis and beyond. Oncogene 27: 6194–6206.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489.
Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al. (2000). The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20: 6638–6645.
Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA et al. (2000). The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6: 1389–1399.
Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M et al. (2010). TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL. PLoS One 5: e8620.
Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M . (2005). Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64: 854–858.
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M . (2004). Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297–305.
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X . (1998). Bid, a bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface receptors. Cell 94: 481–490.
Lutter M, Fang M, Luo X, Nishijima M, Xie X, Wang X . (2000). Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat Cell Biol 2: 754–761.
Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D et al. (1997). A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7: 1003–1006.
Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA . (2005). Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65: 11447–11458.
McKenzie M, Liolitsa D, Hanna MG . (2004). Mitochondrial disease: mutations and mechanisms. Neurochem Res 29: 589–600.
Meier P, Finch A, Evan G . (2000). Apoptosis in development. Nature 407: 796–801.
Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW et al. (2002). The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277: 45162–45171.
Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY et al. (1999). Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6: 1048–1053.
Moscat J, Diaz-Meco MT, Wooten MW . (2007). Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 32: 95–100.
Nagata S . (1997). Apoptosis by death factor. Cell 88: 355–365.
Newsom-Davis T, Prieske S, Walczak H . (2009). Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607–623.
Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M . (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981–989.
Nuutinen U, Simelius N, Ropponen A, Eeva J, Matto M, Eray M et al. (2009). PDTC enables type I TRAIL signaling in type II follicular lymphoma cells. Leuk Res 33: 829–836.
Opferman JT, Korsmeyer SJ . (2003). Apoptosis in the development and maintenance of the immune system. Nat Immunol 4: 410–415.
Ou D, Wang X, Metzger DL, Robbins M, Huang J, Jobin C et al. (2005). Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB. Hum Immunol 66: 799–809.
Ozoren N, El-Deiry WS . (2002). Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4: 551–557.
Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS . (2000). The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60: 6259–6265.
Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM . (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815–818.
Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A et al. (1999). Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 274: 38241–38250.
Peter ME, Krammer PH . (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10: 26–35.
Petros AM, Olejniczak ET, Fesik SW . (2004). Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83–94.
Pickart CM . (2004). Back to the future with ubiquitin. Cell 116: 181–190.
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687–12690.
Prasad KV, Prabhakar BS . (2003). Apoptosis and autoimmune disorders. Autoimmunity 36: 323–330.
Prunell GF, Arboleda VA, Troy CM . (2005). Caspase function in neuronal death: delineation of the role of caspases in ischemia. Curr Drug Targets CNS Neurol Disord 4: 51–61.
Rodriguez J, Lazebnik Y . (1999). Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 13: 3179–3184.
Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH . (2001). Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 8: 1006–1016.
Rossin A, Derouet M, Abdel-Sater F, Hueber AO . (2009). Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 419: 185–192.
Ryu BK, Lee MG, Chi SG, Kim YW, Park JH . (2001). Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15–19.
Said TM, Paasch U, Glander HJ, Agarwal A . (2004). Role of caspases in male infertility. Hum Reprod Update 10: 39–51.
Salvesen GS, Duckett CS . (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401–410.
Sanchez Mejia RO, Friedlander RM . (2001). Caspases in Huntington's disease. Neuroscientist 7: 480–489.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675–1687.
Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T et al. (1997a). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7: 831–836.
Schneider TJ, Grillot D, Foote LC, Nunez GE, Rothstein TL . (1997b). Bcl-x protects primary B cells against Fas-mediated apoptosis. J Immunol 159: 4834–4839.
Schneider-Brachert W, Tchikov V, Merkel O, Jakob M, Hallas C, Kruse ML et al. (2006). Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest 116: 2901–2913.
Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J et al. (2004). Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21: 415–428.
Schutze S, Tchikov V, Schneider-Brachert W . (2008). Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 9: 655–662.
Scorrano L . (2008). Caspase-8 goes cardiolipin: a new platform to provide mitochondria with microdomains of apoptotic signals? J Cell Biol 183: 579–581.
Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al. (2003). TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107: 2250–2256.
Sharp DA, Lawrence DA, Ashkenazi A . (2005). Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280: 19401–19409.
Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA et al. (2007). Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400–11405.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818–821.
Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D et al. (2000). Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288: 2354–2357.
Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK . (2009). Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428–432.
Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H . (2002). Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21: 4520–4530.
Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599–609.
Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J et al. (2001). A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410: 112–116.
Strasser A, Harris AW, Huang DC, Krammer PH, Cory S . (1995). Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14: 6136–6147.
Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R et al. (2001). Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 280: 788–797.
Tafani M, Karpinich NO, Hurster KA, Pastorino JG, Schneider T, Russo MA et al. (2002). Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem 277: 10073–10082.
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S et al. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94–100.
Tepper CG, Seldin MF . (1999). Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94: 1727–1737.
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517–521.
Thome M, Tschopp J . (2001). Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 1: 50–58.
van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P . (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 9: 1031–1042.
Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H et al. (2009). X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 284: 34553–34560.
Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. (2005). Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280: 40599–40608.
Varfolomeev E, Vucic D . (2008). (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 7: 1511–1521.
Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL et al. (1998). Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9: 267–276.
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE et al. (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102: 43–53.
Vitovski S, Phillips JS, Sayers J, Croucher PI . (2007). Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282: 31601–31609.
Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68: 7956–7965.
Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. (2007). Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13: 1070–1077.
Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A et al. (2003). TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361: 2036–2043.
Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ . (2001). Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98: 13884–13888.
Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ . (1996). BID: a novel BH3 domain-only death agonist. Genes Dev 10: 2859–2869.
Wang X . (2001). The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922–2933.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727–730.
Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. (2004). De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694–699.
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673–682.
Wilson NS, Dixit V, Ashkenazi A . (2009). Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 10: 348–355.
Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS . (1999). Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59: 2770–2775.
Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A et al. (2000). Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12: 633–642.
Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B et al. (1999). Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886–891.
Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T . (2007). Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep 18: 1239–1242.
Youle RJ, Strasser A . (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47–59.
Yue HH, Diehl GE, Winoto A . (2005). Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 12: 94–97.
Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P . (2004). TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104: 2044–2050.
Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C et al. (2008). TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214: 117–125.
Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z et al. (2010). Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464: 1058–1061.
Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P . (2003). Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869–2881.
Zhao X, Liu Y, Ma Q, Wang X, Jin H, Mehrpour M et al. (2009). Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun 378: 21–26.
Zheng SJ, Jiang J, Shen H, Chen YH . (2004). Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. J Immunol 173: 5652–5658.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors are full-time employees of Genentech, Inc.
Rights and permissions
About this article
Cite this article
Gonzalvez, F., Ashkenazi, A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29, 4752–4765 (2010). https://doi.org/10.1038/onc.2010.221
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.221
Keywords
This article is cited by
-
Co-overexpression of TRAIL and Smac sensitizes MDA-MB-231 cells to radiation through apoptosis depending on mitochondrial pathway
Radiation and Environmental Biophysics (2022)
-
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
Scientific Reports (2021)
-
Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia
Pharmacological Reports (2020)
-
Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo
Investigational New Drugs (2020)
-
Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death
Metabolic Brain Disease (2020)